These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 18203319

  • 1. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
    Hara T, Ogawa F, Muroi E, Komura K, Takenaka M, Hasegawa M, Fujimoto M, Sato S.
    J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
    [Abstract] [Full Text] [Related]

  • 2. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
    Kodera M, Hayakawa I, Komura K, Yanaba K, Hasegawa M, Takehara K, Sato S.
    J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
    [Abstract] [Full Text] [Related]

  • 3. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
    Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S.
    J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
    [Abstract] [Full Text] [Related]

  • 4. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
    Russo K, Hoch S, Dima C, Varga J, Teodorescu M.
    J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
    [Abstract] [Full Text] [Related]

  • 5. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
    Kuwatsuka Y, Ogawa F, Iwata Y, Komura K, Muroi E, Hara T, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S.
    Autoimmunity; 2009 Feb; 42(2):120-5. PubMed ID: 19021012
    [Abstract] [Full Text] [Related]

  • 6. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K.
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [Abstract] [Full Text] [Related]

  • 7. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
    Iwata Y, Ogawa F, Komura K, Muroi E, Hara T, Shimizu K, Hasegawa M, Fujimoto M, Tomita Y, Sato S.
    Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
    [Abstract] [Full Text] [Related]

  • 8. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M, Vidali M, De Andrea M, Azzimonti B, Airò P, D'Ambrosio R, Riboldi P, Meroni PL, Albano E, Shoenfeld Y, Gariglio M, Landolfo S.
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [Abstract] [Full Text] [Related]

  • 9. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
    Nishijima C, Sato S, Takehara K.
    J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
    [Abstract] [Full Text] [Related]

  • 10. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y, Yoshizaki A, Ogawa F, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S.
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [Abstract] [Full Text] [Related]

  • 11. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S, Hasegawa M, Nagaoka T, Takamatsu Y, Yazawa N, Ihn H, Kikuchi K, Takehara K.
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [Abstract] [Full Text] [Related]

  • 12. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
    Hayakawa I, Hasegawa M, Takehara K, Sato S.
    Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
    [Abstract] [Full Text] [Related]

  • 13. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.
    Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, Sato S.
    Clin Exp Immunol; 2004 Nov; 138(2):357-63. PubMed ID: 15498049
    [Abstract] [Full Text] [Related]

  • 14. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
    Tomita H, Ogawa F, Hara T, Yanaba K, Iwata Y, Muroi E, Yoshizaki A, Komura K, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S.
    J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
    [Abstract] [Full Text] [Related]

  • 15. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
    Hayakawa I, Hasegawa M, Matsushita T, Yanaba K, Kodera M, Komura K, Takehara K, Sato S.
    Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
    [Abstract] [Full Text] [Related]

  • 16. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
    Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, Sato S.
    J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
    [Abstract] [Full Text] [Related]

  • 17. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen JS, Steiner G.
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [Abstract] [Full Text] [Related]

  • 18. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis.
    Hasegawa M, Sato S, Yanaba K, Komura K, Yamazaki M, Takehara K.
    Ann Rheum Dis; 2004 Nov; 63(11):1514-7. PubMed ID: 15479907
    [Abstract] [Full Text] [Related]

  • 19. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S, Komura K, Hasegawa M, Fujimoto M, Takehara K.
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [Abstract] [Full Text] [Related]

  • 20. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, Medsger TA.
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.